-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Mental illness is also called a mental disorder, and this type of disease can cause a series of disorders in the patient's brain function
.
It is understood that the clinical characteristics of mental patients have different clinical characteristics, and the cognition, emotion, behavior and will of the patients are different
.
For patients with mental illness, psychotherapy and drug therapy are the two main treatment methods.
Rapid social changes may have caused an overall increase in people's psychological pressure and stress levels.
In recent years, the prevalence of mental disorders has generally increased, and the mental illness Patients with disorders usually need long-term medication.
Therefore, in recent years, with the continuous enhancement of people's health awareness, medication for mental disorders has maintained a continuous growth trend
.
Antipsychotics are also called strong tranquilizers or nerve blockers
.
It is a group of drugs used to treat schizophrenia and other psychotic disorders
.
The usual therapeutic dose does not affect the patient's intelligence and consciousness, but can effectively control the patient's psychomotor excitement, hallucinations, delusions, hostile emotions, thinking disorders and abnormal behaviors
.
The data shows that the total size of the mental disorder drug market in sample hospitals has continued to grow.
From 2016 to 2019, this market has risen from 4.
173 billion yuan to 5.
732 billion yuan, with an average annual compound growth rate of 12.
80%
.
It is predicted that in 2021, the total size of the drug market for mental disorders in China's sample hospitals may reach 6.
049 billion yuan, and the market size is expected to reach 6.
401 billion yuan in 2022
.
In addition, according to data from sample hospitals in the PDB database in 2020, antidepressants currently have the largest sales, accounting for more than 44%, followed by hypnotic/sedatives, antipsychotics and anxiolytics
.
Among them, depression is a common depressive disorder, with significant and lasting depression as the main clinical feature, and it is the main type of mood disorder
.
Antidepressants refer to a group of psychotropic drugs mainly used to treat mental illnesses with emotional depression as the prominent symptom
.
As my country pays more and more attention to people’s mental health, the market size of antidepressant drugs in my country has grown year by year from 2016 to 2019
.
According to data, from 2016 to 2019, the sales of terminal antidepressant drugs in public medical institutions in China increased from 5.
84 billion yuan to 9.
03 billion yuan
.
It is estimated that in 2021 and 2022, the sales of terminal antidepressant drugs in public medical institutions in China may reach 9.
56 billion yuan and 10.
57 billion yuan respectively
.
It is understood that China's pharmaceutical companies are continuously increasing their efforts in the development of antipsychotic drugs
.
Among them, Luye Pharma’s first self-developed second-generation antipsychotic long-acting injection, Recinto® (Risperidone Microspheres for Injection (II)), was approved for marketing on January 12, 2021, providing patients with Come to new medication options
.
In addition, some companies recently announced that the company has completed hundreds of millions of yuan in B+ round of financing to promote the research and development of pipelines for products such as mental sustained-release preparations
.
The company said that the market for mental diseases is huge, and there are also many unmet clinical needs.
The company will focus on the research and development of innovative drugs and high-end preparations in this field
.
With the continuous innovation and development of drugs, patients have also ushered in more choices in drug treatment
.
According to industry insiders, the psychiatric drug market is huge, and pharmaceutical companies need to continue to focus on this area, develop more products around the unmet treatment needs of more patients, so as to improve the effectiveness, safety and compliance of patients' medication
.
.
It is understood that the clinical characteristics of mental patients have different clinical characteristics, and the cognition, emotion, behavior and will of the patients are different
.
For patients with mental illness, psychotherapy and drug therapy are the two main treatment methods.
Rapid social changes may have caused an overall increase in people's psychological pressure and stress levels.
In recent years, the prevalence of mental disorders has generally increased, and the mental illness Patients with disorders usually need long-term medication.
Therefore, in recent years, with the continuous enhancement of people's health awareness, medication for mental disorders has maintained a continuous growth trend
.
Antipsychotics are also called strong tranquilizers or nerve blockers
.
It is a group of drugs used to treat schizophrenia and other psychotic disorders
.
The usual therapeutic dose does not affect the patient's intelligence and consciousness, but can effectively control the patient's psychomotor excitement, hallucinations, delusions, hostile emotions, thinking disorders and abnormal behaviors
.
The data shows that the total size of the mental disorder drug market in sample hospitals has continued to grow.
From 2016 to 2019, this market has risen from 4.
173 billion yuan to 5.
732 billion yuan, with an average annual compound growth rate of 12.
80%
.
It is predicted that in 2021, the total size of the drug market for mental disorders in China's sample hospitals may reach 6.
049 billion yuan, and the market size is expected to reach 6.
401 billion yuan in 2022
.
In addition, according to data from sample hospitals in the PDB database in 2020, antidepressants currently have the largest sales, accounting for more than 44%, followed by hypnotic/sedatives, antipsychotics and anxiolytics
.
Among them, depression is a common depressive disorder, with significant and lasting depression as the main clinical feature, and it is the main type of mood disorder
.
Antidepressants refer to a group of psychotropic drugs mainly used to treat mental illnesses with emotional depression as the prominent symptom
.
As my country pays more and more attention to people’s mental health, the market size of antidepressant drugs in my country has grown year by year from 2016 to 2019
.
According to data, from 2016 to 2019, the sales of terminal antidepressant drugs in public medical institutions in China increased from 5.
84 billion yuan to 9.
03 billion yuan
.
It is estimated that in 2021 and 2022, the sales of terminal antidepressant drugs in public medical institutions in China may reach 9.
56 billion yuan and 10.
57 billion yuan respectively
.
It is understood that China's pharmaceutical companies are continuously increasing their efforts in the development of antipsychotic drugs
.
Among them, Luye Pharma’s first self-developed second-generation antipsychotic long-acting injection, Recinto® (Risperidone Microspheres for Injection (II)), was approved for marketing on January 12, 2021, providing patients with Come to new medication options
.
In addition, some companies recently announced that the company has completed hundreds of millions of yuan in B+ round of financing to promote the research and development of pipelines for products such as mental sustained-release preparations
.
The company said that the market for mental diseases is huge, and there are also many unmet clinical needs.
The company will focus on the research and development of innovative drugs and high-end preparations in this field
.
With the continuous innovation and development of drugs, patients have also ushered in more choices in drug treatment
.
According to industry insiders, the psychiatric drug market is huge, and pharmaceutical companies need to continue to focus on this area, develop more products around the unmet treatment needs of more patients, so as to improve the effectiveness, safety and compliance of patients' medication
.
